Clinical Trials · NCT00353496
Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Ipsen
- Enrollment
- 264
- Start date
- Jun 2006
- Locations
- 71 sites, 15 countries
- Primary endpoint
- Progression-Free Survival (PFS)